CTNM net incomeQ3 2026-$18.70M
CTNM net income was -$18.70M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$12.79M a year earlier. For the full fiscal 2025 it was -$59.98M, compared with -$42.26M in fiscal 2024.
Contineum Therapeutics Inc. (CTNM) financials
For the twelve months ended Sep 30, 2026, Contineum Therapeutics Inc. reported -$63.46M of net income.
- Net income, TTM
- -$63.46M
- Free cash flow, TTM
- -$52.23M
- EPS, diluted, TTM
- -$1.76
- Cash
- $75.20M
- Market cap
- $374.0M
FY2023FY2024
FY2023FY2025
FY2023FY2025
CTNM revenue and earnings growth
CTNM EPSQ3 2026-$0.49
CTNM diluted EPS was -$0.49 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.45 a year earlier. For the full fiscal 2025 it was -$2.17.
CTNM free cash flowQ3 2026-$11.06M
CTNM free cash flow was -$11.06M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$12.29M a year earlier. For the full fiscal 2025 it was -$55.54M, compared with -$33.36M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | - | $0 | $50.00M |
| Research and development | $51.52M | $38.42M | $27.60M |
| Selling, general and admin | $16.54M | $12.47M | $6.32M |
| Operating income | -$68.06M | -$50.89M | $16.08M |
| Interest expense | - | $0 | $208.0K |
| Pre-tax income | -$60.14M | -$42.26M | $23.17M |
| Income tax | $0 | $0 | $450.0K |
| Net income | -$59.98M | -$42.26M | $22.72M |
| EPS, basic | -$2.17 | -$2.18 | $1.36 |
| EPS, diluted | -$2.17 | -$2.18 | $0.08 |
| Diluted shares | 27.7M | 19.4M | 3.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $75.60M | $21.94M | $15.53M |
| Short-term investments | $187.29M | $182.82M | $109.66M |
| Current assets | $267.92M | $206.39M | $127.71M |
| Total assets | $276.64M | $212.85M | $130.39M |
| Current liabilities | $9.74M | $9.97M | $5.48M |
| Total liabilities | $15.65M | $14.78M | $5.70M |
| Shareholders' equity | $260.99M | $198.07M | -$67.94M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$55.31M | -$32.84M | $19.35M |
| Capital expenditures | $231.0K | $514.0K | $414.0K |
| Free cash flow | -$55.54M | -$33.36M | $18.93M |
| Investing cash flow | -$3.71M | -$69.74M | -$65.57M |
| Financing cash flow | $112.69M | $109.00M | $56.18M |
| Stock-based compensation | $10.04M | $6.80M | $2.22M |
| Depreciation and amortization | $323.0K | $258.0K | $195.0K |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $0 | $0 | $0 | $0 | $0 |
| Research and development | $15.98M | $12.70M | $11.65M | $12.76M | $10.99M | $14.06M | $13.71M | $13.02M | $9.73M | $7.90M | $7.78M | $8.01M |
| Selling, general and admin | $4.98M | $4.73M | $5.26M | $4.36M | $3.94M | $3.84M | $4.40M | $4.03M | $3.25M | $3.04M | $2.15M | $1.66M |
| Operating income | -$20.97M | -$17.43M | -$16.90M | -$17.11M | -$14.93M | -$17.90M | -$18.11M | -$17.05M | -$12.97M | -$10.94M | -$9.93M | -$9.68M |
| Interest expense | - | - | - | - | - | - | - | $0 | $0 | $0 | $0 | $0 |
| Pre-tax income | - | - | - | - | - | - | - | -$14.56M | -$10.27M | -$9.01M | -$8.42M | -$7.93M |
| Income tax | - | - | - | - | - | - | - | $0 | $0 | $0 | $0 | -$161.0K |
| Net income | -$18.70M | -$15.15M | -$14.46M | -$15.16M | -$12.79M | -$16.04M | -$15.99M | -$14.56M | -$10.27M | -$9.01M | -$8.42M | -$7.77M |
| EPS, basic | -$0.49 | -$0.40 | -$0.39 | -$0.48 | -$0.45 | -$0.62 | -$0.62 | - | -$0.40 | -$0.39 | -$3.55 | - |
| EPS, diluted | -$0.49 | -$0.40 | -$0.39 | -$0.48 | -$0.45 | -$0.62 | -$0.62 | - | -$0.40 | -$0.39 | - | - |
| Diluted shares | 38.4M | 37.5M | 37.3M | - | 28.1M | 25.9M | 25.9M | - | 25.7M | 23.4M | 2.4M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $75.20M | $14.71M | $20.16M | $75.60M | $42.63M | $20.78M | $22.47M | $21.94M | $40.89M | $77.23M | $16.26M | $15.53M |
| Short-term investments | $169.29M | $221.84M | $226.17M | $187.29M | $139.77M | $154.70M | $168.24M | $182.82M | $173.02M | $141.42M | $101.64M | $109.66M |
| Current assets | $249.74M | $242.58M | $252.96M | $267.92M | $184.93M | $176.84M | $192.13M | $206.39M | $215.14M | $220.32M | $119.71M | $127.71M |
| Total assets | $256.99M | $250.37M | $261.35M | $276.64M | $190.85M | $182.89M | $198.26M | $212.85M | $216.03M | $221.35M | $123.56M | $130.39M |
| Current liabilities | $8.03M | $6.53M | $6.66M | $9.74M | $6.36M | $7.21M | $8.95M | $9.97M | $5.81M | $3.74M | $6.23M | $5.48M |
| Total liabilities | $11.57M | $10.71M | $11.31M | $15.65M | $10.38M | $11.50M | $13.50M | $14.78M | $5.81M | $3.85M | $6.57M | $5.70M |
| Shareholders' equity | $245.42M | $239.66M | $250.04M | $260.99M | $180.47M | $171.39M | $184.77M | $198.07M | $210.23M | $217.50M | -$75.63M | -$67.94M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.06M | -$11.50M | -$16.27M | -$13.04M | -$12.20M | -$15.66M | -$14.41M | -$10.20M | -$6.17M | -$8.50M | -$7.97M | -$10.70M |
| Capital expenditures | $0 | $6.0K | $312.0K | $42.0K | $98.0K | $44.0K | $47.0K | $166.0K | $82.0K | $119.0K | $147.0K | $309.0K |
| Free cash flow | -$11.06M | -$11.51M | -$16.58M | -$13.08M | -$12.29M | -$15.71M | -$14.46M | -$10.37M | -$6.25M | -$8.62M | -$8.12M | -$11.01M |
| Investing cash flow | $50.95M | $4.85M | -$39.31M | -$47.45M | $14.94M | $13.88M | $14.91M | -$9.39M | -$30.18M | -$38.90M | $8.73M | $9.03M |
| Financing cash flow | $20.59M | $1.20M | $129.0K | $93.47M | $19.11M | $91.0K | $24.0K | $642.0K | $13.0K | $108.36M | -$18.0K | -$321.0K |
| Stock-based compensation | $4.86M | $3.84M | $3.82M | $2.48M | $2.57M | $2.42M | $2.57M | $2.25M | $2.29M | $1.49M | $768.0K | $759.0K |
| Depreciation and amortization | $81.0K | $134.0K | $83.0K | $85.0K | $81.0K | $79.0K | $78.0K | $75.0K | $62.0K | $60.0K | $61.0K | $37.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | - | -100.0% | - | - |
| Current ratio | 31.11 | 37.17 | 38.00 | 27.50 | 29.07 | 24.51 | 21.47 | 20.69 | 37.06 | 58.92 | 19.20 | 23.29 |
Source: XBRL data Contineum Therapeutics Inc. files with the SEC, latest filing dated Nov 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CTNM peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CTNM | - | - | -$63.46M | - | $374.0M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
CTNM FAQ
6 questionsIs CTNM profitable?
No. Contineum Therapeutics Inc. reported a net loss of $63.46M for the twelve months ended Sep 30, 2026.How much cash and debt does CTNM have?
Contineum Therapeutics Inc. reported $75.20M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is CTNM free cash flow?
Contineum Therapeutics Inc. generated -$52.23M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$51.87M less capital expenditures.What is CTNM earnings per share?
Diluted earnings per share were -$1.76 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did CTNM last report financial results?
The latest statements here come from Contineum Therapeutics Inc.'s 10-Q filed on Nov 3, 2026, covering the period ended Sep 30, 2026.Where does this CTNM financial data come from?
Quantisnow builds these statements from the structured XBRL data Contineum Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.